Medindia

X

Cempra Pharmaceuticals Will Present New Data on cem-101 and cem-102 at the Infectious Disease Society Of America, 47th Annual Meeting

Friday, October 23, 2009 General News J E 4
Advertisement


CHAPEL HILL, N.C., Oct. 22 Cempra Pharmaceuticals today announced its schedule of oral and poster presentations at the Infectious Disease Society of America, 47th Annual Meeting, in Philadelphia on Oct. 29 to Nov. 1, 2009.

Four presentations on CEM-102 will present results on the compound's in vitro activity against gram-positive organisms, featuring resistance frequencies, and the drug's PK-PD profile when a novel dosing regimen is used. A fifth presentation will present in vitro data on CEM-101's activity against multidrug-resistant S. pneumoniae.

CEM-102 is an oral formulation of fusidic acid, an agent with activity against gram-positive organisms including methicillin-resistant S. aureus (MRSA). The compound is Cempra's lead molecule currently in Phase 2/3 clinical trials, vs. linezolid, being investigated for the treatment of acute bacterial skin structure infections (ABSSIs). This novel adaptive trial is expected to flow into a Phase 3 pivotal trial in Q1 2010. CEM-101, Cempra's novel oral fluoroketolide, will soon enter a Phase 2 clinical trial for moderate-to-moderately severe community-acquired bacterial pneumonia (CABP). CEM-101 has shown potent activity against S. pneumoniae, including multidrug-resistant isolates.

Cempra Pharmaceuticals IDSA 2009 Schedule At-A-Glance

Friday, October 30, 2009

Saturday, October 31, 2009

About Cempra PharmaceuticalsFounded in 2006, Cempra Pharmaceuticals is a privately-held, clinical-stage biotechnology company focused on developing antibacterials to address critical medical needs. Two lead products, both in late-stage clinical trials, address the urgent and increasing need for new treatments targeting drug-resistant bacterial infections in the hospital and in the community. Cempra is well-funded and is committed to developing commercially viable products through consideration of pricing and reimbursement issues throughout its products' lifecycles. The company is also utilizing its proprietary chemistry technology to develop macrolides without antibacterial activity for non-antibiotic uses in motilin receptor activity, anti-inflammatory activity and GnRH receptor antagonism. Additional information about Cempra can be found at www.cempra.com.

-- Poster presentation: "Contemporary Activity of CEM-102 (Fusidic Acid [FA]) Against Canadian Isolates of Staphylococci and Streptococci (2001-2006)" Time: On display 12:30 to 2 p.m. EDT, Poster Hall A, Poster # 202 Paul R. Rhomberg, B.S., Leah N. Woosley, B.S., Helio S. Sader, M.D., Ph.D., Ronald N. Jones, M.D., FIDSA JMI Lab., North Liberty, IA. Presenter: Ronald N. Jones, M.D., FIDSA -- Poster Presentation: "Update on the Spectrum of CEM-102 (Fusidic Acid [FA]) Against Contemporary Wildtype (WT) Bacterial Species Including Mutational Resistance Analysis and Synergy Testing" Time: On display 12:30 to 2 p.m. EDT, Poster Hall A, Poster # 203 Paul R. Rhomberg, B.S., Rodrigo E. Mendes, Ph.D., Holly K. Becker, B.S., Kelley A. Fedler, B.S., Helio S. Sader, M.D., Ph.D., Ronald N. Jones, M.D., FIDSA JMI Lab., North Liberty, IA. Presenter: Ronald N. Jones, M.D., FIDSA -- Poster presentation: "CEM-101, A Novel Fluoroketolide: Activity Against Recent (2008) Isolates of Multidrug-Resistant (MDR) S. pneumoniae (SPN)" Time: On display 12:30 to 2 p.m. EDT, Poster Hall A, Poster # 208 Ronald N. Jones, M.D., FIDSA(1), Matthew G. Stilwell, B.S.(1), Helio S. Sader, M.D., Ph.D.(1), Prabha Fernandes, Ph.D.(2) (1)JMI Lab., North Liberty, IA, (2)Cempra Pharmaceuticals, Chapel Hill, NC. Presenter: Ronald N. Jones, M.D., FIDSA -- Poster presentation: "Performance of CEM-102 (Fusidic Acid [FA]) Susceptibility Testing Reagents; Broth Microdilution, Disk Diffusion and Etest Methods" Time: On display 12:30 to 2 p.m. EDT, Poster Hall A, Poster # 261 Paul R. Rhomberg, B.S., Leah N. Woosley, B.S., Helio S. Sader, M.D., Ph.D., Ronald N. Jones, M.D., FIDSA JMI Lab., North Liberty, IA. Presenter: Ronald N. Jones, M.D., FIDSA

SOURCE Cempra Pharmaceuticals
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
TEI Biosciences Introduces SurgiMend(R) PRS for Br...
S
Burner Balm Blasts Continued UK Attacks Over New L...